Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06298799
Other study ID # GEN-GE-001-IL
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date January 1, 2025

Study information

Verified date March 2024
Source GENGE
Contact Hila Kfir
Phone +972-523313350
Email hilaz28@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this retrospective study is to assess whether a selection of genetic variants may allow us to identify individuals who will have a satisfactory response after GLP-1 treatment in terms of weight loss, sugar level reduction, and adverse events. Participants will The study consists of a single visit at the diabetes unit clinic at the involved study sites. The following will be performed for every subject at the study screening enrollment visit: - Informed consent - Study eligibility (Inclusion / Exclusion criteria) - Collection of demographic data (age (date of birth), gender, ethnic origin) - General and T2DM medical history review (per subject file) - Concomitant medication review (at enrollment) - Physical attributes (Body Weight, Height, BMI) - Allocation to study cohort and study subgroup - Saliva and blood collection for genetic tests - Self-reported questionnaire for Ozempic (Semaglutide) experience


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Diagnosed with type 2 diabetes (for participant in Cohort A) or Obese (for participant in Cohort B) and treated with Ozempic (Semaglutide) S.C. injection for at least 24 weeks. 2. Subject is male/female between 18 to 80 years old (both inclusive) at the time of enrollment. 3. Subject BMI above 30 kg/m2 at treatment initiation. 4. Subject does not belong to any vulnerable population, is willing and able to provide written informed consent prior to any study procedure. 5. Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol. Exclusion Criteria: 1. Subject falls under contraindications to Ozempic (Semaglutide) label 2. Subject known or suspected for hypersensitivity to any GLP-1RA or related products, or allergic constitution 3. Subjects suffers from any other condition affecting body weight. 4. Subject with history of chronic or acute pancreatitis 5. Subject have a history of a major cardiovascular and/or cerebrovascular disease within the 6 months before screening. 6. Presence or history of malignant neoplasm within 5 years prior to screening day. 7. Subject suffers from any renal impairment (Cr > 2 mg/dl). 8. Subject suffers from any impaired hepatic function (ALT, AST or GGT 2-fold higher than normal upper limit). 9. Any disorder, which in the investigator's opinion might jeopardize patient's safety or compliance with the protocol. 10. Subject is a female who is pregnant, breastfeeding or intends to become pregnant or is of child bearing potential without medically acceptable methods of contraception. 11. Participation in another clinical study in prior 4 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
DNA Sequencing and Analysis
DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
differential expression analysis with RNA-sequencing (RNA seq) experiments
Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules

Locations

Country Name City State
Israel Rambem medical center Haifa

Sponsors (1)

Lead Sponsor Collaborator
GENGE

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Genetic variants and miRNA expressions associated with side effects. Identify genetic variants and miRNA expressions that affects the response to GLP-1 treatment associated with side effects. 12 months
Other Demographic parameters that affect GLP1 AG therapy. To identify demographic parameters that affect the response to GLP1 AG therapy. 12 months
Primary Genetic variants and miRNA expressions associated with changes in BMI. Identify genetic variants and miRNA expressions that affects the response to GLP-1 treatment associated with changes in BMI. 12 months
Secondary Genetic variants and miRNA expressions associated with changes in A1c. Identify genetic variants and miRNA expressions that affects the response to GLP-1 treatment associated with changes in A1c. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2